// App-Quantinova.ai

2134 : Rational design of selective MNK 1 and 2 kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia patients

Researchers

Presenter

  • Kassoum Nacro

Principal Investigators

  • Melvyn Wai Tuck Ho

  • Yoon Sheng Yeap

  • Lohitha Rao Chennamaneni

  • Shi Hua Ang

  • Eldwin Sum Wai Tan

  • Athisayamani Jeyaraj Duraiswamy

  • Sharon Lim

  • Boping Liu

  • Esther Hongqian Ong

  • Meng Ling Choong

  • Shi Jing Tai

  • Vithya Manoharan

  • Vishal Pendharkar

  • Lijun Ding

  • Yun Shan Chew

  • Joma Kanikadu Joy

  • John LW Kuan

  • Perlyn Z. Kwek

  • Anders Poulsen

  • May Ann Lee

  • Kanda Sangthongpitag

  • Charles Chuah

  • Tiong S. Ong

  • Jeffrey Hill

  • Thomas H. Keller

  • Alex Matter

Medical Centers

  • Experimental Therapeutics Centre, Singapore, Singapore

  • Institute of Chemical & Engineering Sciences, Singapore, Singapore

  • Duke-NUS Medical School, Singapore, Singapore

Locations

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved